Arcturus Therapeutics Q4 2025 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Should l Buy ARCT?
Source: seekingalpha
- Clinical Trial Progress: Arcturus is advancing its ARCT-032 Phase II trial, set to initiate a 12-week study in the first half of 2026, enrolling 20 participants to focus on safety and early clinical benefits, potentially providing critical data for cystic fibrosis treatment.
- Financial Performance Decline: The company reported a year-over-year revenue drop of $70.3 million and a quarterly decline of $15.6 million, primarily due to reduced CSL collaboration activity, reflecting challenges in the commercialization process, although R&D expenses decreased by $83 million, indicating efforts in cost control.
- Strong Cash Position: As of December 31, 2025, the company held $232.8 million in cash and equivalents, with a projected cash runway extending into the second quarter of 2028, providing ample funding for future R&D and clinical trials.
- Regulatory Pathway Clarity: Management plans to hold Type C meetings with regulators in the first half of 2026 to clarify clinical development steps for ARCT-810, ensuring that trial designs for both adult and pediatric populations meet regulatory requirements, thereby facilitating the path to market for key therapeutics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARCT
Wall Street analysts forecast ARCT stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 6.650
Low
7.00
Averages
14.00
High
20.00
Current: 6.650
Low
7.00
Averages
14.00
High
20.00
About ARCT
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cathie Wood Increases Holdings in Three Stocks Amid Market Volatility
- Circle Internet Group Dynamics: Circle Internet Group's stock plummeted 20% on Tuesday due to concerns over cryptocurrency regulation discussions, yet it reported revenue growth of 53%, 66%, and 77% in its first three quarters; Cathie Wood's decision to buy more shares at this low point reflects her confidence in its long-term potential despite regulatory risks.
- Arcturus Therapeutics Outlook: Arcturus Therapeutics reported a sharp revenue decline for three consecutive years, with projections indicating a further drop to one-fifth of its 2022 revenue by 2026; however, positive clinical trial developments and an extended cash runway to Q2 2028 may provide investor reassurance, prompting Wood to increase her stake, indicating optimism in the biotech sector.
- 10x Genomics Steady Growth: 10x Genomics, a provider of life sciences tools, has seen significant revenue growth in seven of the past eight years, and despite profitability challenges, Wood's continued purchases over four consecutive trading days highlight her belief in its long-term success, particularly with the promising Chromium platform.
- Market Environment Impact: Despite Ark Invest's largest fund declining 11% this year, nearly three times the market's drop, Cathie Wood's strategy of increasing her holdings in these stocks during market volatility suggests a bullish outlook for future rebounds, potentially attracting more investor interest in her investment approach.
See More
Cathie Wood Quietly Adds to Three Stocks Amid Market Decline
- Figma Price Volatility: Figma's stock has plummeted 83% from last summer's highs, yet its latest quarterly revenue growth accelerated to 40% year-over-year, indicating vulnerability amid shifting market sentiment and competitive pressures in the cloud platform sector.
- Arcturus Therapeutics Investment: Ark Invest has steadily increased its stake in Arcturus Therapeutics over the past week, despite the company's revenue sharply declining over the past three years and expected to be halved again this year, highlighting investor interest in its mRNA technology for rare disease treatments.
- 10x Genomics Growth Struggles: 10x Genomics has seen a ninefold revenue increase over the past eight years, but its stock price has fallen from its IPO price of $38 to the current $18.38, reflecting a lack of profitability and poor future revenue guidance despite strong market demand.
- Market Environment Challenges: With major market indexes declining for four consecutive weeks, Cathie Wood's cautious investment strategy, adding to these three stocks, reflects her confidence in their long-term potential despite facing short-term market pressures.
See More
Cathie Wood Increases Stakes in Figma, Arcturus, and 10x Genomics
- Figma Price Drop: Figma's stock has plummeted 83% from last year's peak, and while analysts predict a significant slowdown in growth over the next two years, its latest quarter showed a 40% year-over-year revenue increase, indicating strong market demand that may attract investor interest.
- Arcturus Financial Status: Arcturus Therapeutics has seen its revenue decline for three consecutive years, with expectations of another 50% cut this year; however, its strong liquidity and the potential of its leading drug candidate led Cathie Wood to increase her stake three times last week, reflecting confidence in its future.
- 10x Genomics Growth Potential: 10x Genomics has experienced a ninefold revenue increase over the past eight years, yet its stock is currently trading at half its IPO price and has yet to achieve profitability; nevertheless, its leading position in single-cell genomic analysis and market demand continue to support its future growth prospects.
- Market Environment Challenges: Despite Cathie Wood typically increasing her holdings during market downturns, last week she only added to her positions in Figma, Arcturus, and 10x Genomics, highlighting the current market challenges for investors, particularly as high-valuation tech stocks face competitive pressures.
See More
Arcturus Therapeutics Q4 2025 Earnings Call Insights
- Clinical Trial Progress: Arcturus is advancing its ARCT-032 Phase II trial, set to initiate a 12-week study in the first half of 2026, enrolling 20 participants to focus on safety and early clinical benefits, potentially providing critical data for cystic fibrosis treatment.
- Financial Performance Decline: The company reported a year-over-year revenue drop of $70.3 million and a quarterly decline of $15.6 million, primarily due to reduced CSL collaboration activity, reflecting challenges in the commercialization process, although R&D expenses decreased by $83 million, indicating efforts in cost control.
- Strong Cash Position: As of December 31, 2025, the company held $232.8 million in cash and equivalents, with a projected cash runway extending into the second quarter of 2028, providing ample funding for future R&D and clinical trials.
- Regulatory Pathway Clarity: Management plans to hold Type C meetings with regulators in the first half of 2026 to clarify clinical development steps for ARCT-810, ensuring that trial designs for both adult and pediatric populations meet regulatory requirements, thereby facilitating the path to market for key therapeutics.
See More
Arcturus Therapeutics Reports Disappointing Earnings
- Disappointing Earnings: Arcturus Therapeutics reported a FY GAAP EPS of -$2.40, missing expectations by $0.24, indicating ongoing challenges in profitability that could undermine investor confidence.
- Revenue Miss: The company generated $82 million in revenue, falling short of expectations by $8.47 million, reflecting weak market demand that may lead to future liquidity issues.
- Operating Expense Reduction: Operating expenses for fiscal year 2025 totaled $158.3 million, a decrease of $89.7 million compared to 2024, showing efforts in cost control, yet insufficient to offset revenue shortfalls.
- Quarterly Expense Analysis: The fourth quarter operating expenses were $38.5 million, down $17.7 million year-over-year, but despite the reduction, the overall financial performance remains poor, potentially impacting future investment decisions.
See More
Arcturus Therapeutics Set to Announce Q4 Earnings on March 3rd
- Earnings Announcement Date: Arcturus Therapeutics (ARCT) is set to announce its Q4 earnings on March 3rd after market close, with consensus EPS estimate at -$0.76 and revenue estimate at $14.32 million, indicating financial pressure on the company.
- Historical Performance: Over the past two years, Arcturus has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, demonstrating a degree of reliability in its financial forecasting.
- Estimate Revision Trends: In the last three months, there has been one upward revision and no downward revisions to EPS estimates, suggesting analysts maintain a cautiously optimistic outlook on the company's future performance, possibly reflecting confidence in its products or market strategy.
- Market Reaction Expectations: Despite facing challenges, the market remains attentive to the upcoming earnings report, especially as the current stock price reflects low expectations, potentially offering investors a rebound opportunity.
See More
Cathie Wood Increases Holdings in Three Stocks Amid Market Volatility
- Circle Internet Group Dynamics: Circle Internet Group's stock plummeted 20% on Tuesday due to concerns over cryptocurrency regulation discussions, yet it reported revenue growth of 53%, 66%, and 77% in its first three quarters; Cathie Wood's decision to buy more shares at this low point reflects her confidence in its long-term potential despite regulatory risks.
- Arcturus Therapeutics Outlook: Arcturus Therapeutics reported a sharp revenue decline for three consecutive years, with projections indicating a further drop to one-fifth of its 2022 revenue by 2026; however, positive clinical trial developments and an extended cash runway to Q2 2028 may provide investor reassurance, prompting Wood to increase her stake, indicating optimism in the biotech sector.
- 10x Genomics Steady Growth: 10x Genomics, a provider of life sciences tools, has seen significant revenue growth in seven of the past eight years, and despite profitability challenges, Wood's continued purchases over four consecutive trading days highlight her belief in its long-term success, particularly with the promising Chromium platform.
- Market Environment Impact: Despite Ark Invest's largest fund declining 11% this year, nearly three times the market's drop, Cathie Wood's strategy of increasing her holdings in these stocks during market volatility suggests a bullish outlook for future rebounds, potentially attracting more investor interest in her investment approach.
See More
Cathie Wood Quietly Adds to Three Stocks Amid Market Decline
- Figma Price Volatility: Figma's stock has plummeted 83% from last summer's highs, yet its latest quarterly revenue growth accelerated to 40% year-over-year, indicating vulnerability amid shifting market sentiment and competitive pressures in the cloud platform sector.
- Arcturus Therapeutics Investment: Ark Invest has steadily increased its stake in Arcturus Therapeutics over the past week, despite the company's revenue sharply declining over the past three years and expected to be halved again this year, highlighting investor interest in its mRNA technology for rare disease treatments.
- 10x Genomics Growth Struggles: 10x Genomics has seen a ninefold revenue increase over the past eight years, but its stock price has fallen from its IPO price of $38 to the current $18.38, reflecting a lack of profitability and poor future revenue guidance despite strong market demand.
- Market Environment Challenges: With major market indexes declining for four consecutive weeks, Cathie Wood's cautious investment strategy, adding to these three stocks, reflects her confidence in their long-term potential despite facing short-term market pressures.
See More
Cathie Wood Increases Stakes in Figma, Arcturus, and 10x Genomics
- Figma Price Drop: Figma's stock has plummeted 83% from last year's peak, and while analysts predict a significant slowdown in growth over the next two years, its latest quarter showed a 40% year-over-year revenue increase, indicating strong market demand that may attract investor interest.
- Arcturus Financial Status: Arcturus Therapeutics has seen its revenue decline for three consecutive years, with expectations of another 50% cut this year; however, its strong liquidity and the potential of its leading drug candidate led Cathie Wood to increase her stake three times last week, reflecting confidence in its future.
- 10x Genomics Growth Potential: 10x Genomics has experienced a ninefold revenue increase over the past eight years, yet its stock is currently trading at half its IPO price and has yet to achieve profitability; nevertheless, its leading position in single-cell genomic analysis and market demand continue to support its future growth prospects.
- Market Environment Challenges: Despite Cathie Wood typically increasing her holdings during market downturns, last week she only added to her positions in Figma, Arcturus, and 10x Genomics, highlighting the current market challenges for investors, particularly as high-valuation tech stocks face competitive pressures.
See More
Arcturus Therapeutics Q4 2025 Earnings Call Insights
- Clinical Trial Progress: Arcturus is advancing its ARCT-032 Phase II trial, set to initiate a 12-week study in the first half of 2026, enrolling 20 participants to focus on safety and early clinical benefits, potentially providing critical data for cystic fibrosis treatment.
- Financial Performance Decline: The company reported a year-over-year revenue drop of $70.3 million and a quarterly decline of $15.6 million, primarily due to reduced CSL collaboration activity, reflecting challenges in the commercialization process, although R&D expenses decreased by $83 million, indicating efforts in cost control.
- Strong Cash Position: As of December 31, 2025, the company held $232.8 million in cash and equivalents, with a projected cash runway extending into the second quarter of 2028, providing ample funding for future R&D and clinical trials.
- Regulatory Pathway Clarity: Management plans to hold Type C meetings with regulators in the first half of 2026 to clarify clinical development steps for ARCT-810, ensuring that trial designs for both adult and pediatric populations meet regulatory requirements, thereby facilitating the path to market for key therapeutics.
See More
Arcturus Therapeutics Reports Disappointing Earnings
- Disappointing Earnings: Arcturus Therapeutics reported a FY GAAP EPS of -$2.40, missing expectations by $0.24, indicating ongoing challenges in profitability that could undermine investor confidence.
- Revenue Miss: The company generated $82 million in revenue, falling short of expectations by $8.47 million, reflecting weak market demand that may lead to future liquidity issues.
- Operating Expense Reduction: Operating expenses for fiscal year 2025 totaled $158.3 million, a decrease of $89.7 million compared to 2024, showing efforts in cost control, yet insufficient to offset revenue shortfalls.
- Quarterly Expense Analysis: The fourth quarter operating expenses were $38.5 million, down $17.7 million year-over-year, but despite the reduction, the overall financial performance remains poor, potentially impacting future investment decisions.
See More
Arcturus Therapeutics Set to Announce Q4 Earnings on March 3rd
- Earnings Announcement Date: Arcturus Therapeutics (ARCT) is set to announce its Q4 earnings on March 3rd after market close, with consensus EPS estimate at -$0.76 and revenue estimate at $14.32 million, indicating financial pressure on the company.
- Historical Performance: Over the past two years, Arcturus has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, demonstrating a degree of reliability in its financial forecasting.
- Estimate Revision Trends: In the last three months, there has been one upward revision and no downward revisions to EPS estimates, suggesting analysts maintain a cautiously optimistic outlook on the company's future performance, possibly reflecting confidence in its products or market strategy.
- Market Reaction Expectations: Despite facing challenges, the market remains attentive to the upcoming earnings report, especially as the current stock price reflects low expectations, potentially offering investors a rebound opportunity.
See More
